VSIR and neoplasm: Encouraging results in pre-clinical studies on PD-1-derived CA170 (a small molecule dually targeting PD-L1 and VISTA pathways) reporting high efficacy in the suppression of tumor growth at well-tolerated doses has prompted the advancement of CA170 to clinical trials [59].